The latest generation of cardiovascular stents could dramatically improve on current drug-eluting stent platforms – with better safety profiles and improved healing – but the barriers to entry at FDA could prevent these products from seeing the light of day, some cardiologists warn.
At major cardio meetings this month, stent makers, both start-ups and traditional market leaders, showcased data on several next-gen systems...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?